New research from the Technical University of Munich and Harvard Medical School reveals that popular GLP-1-based drugs, semaglutide (Ozempic) and tirzepatide (Mounjaro), not only promote weight loss but also significantly reduce the risk of heart attacks and strokes in patients with type 2 diabetes. Using real-world insurance data, the study found up to an 18% reduction in major cardiovascular events, confirming powerful heart-protective effects that appear to extend beyond weight control.
from Top Health News -- ScienceDaily https://ift.tt/2DAsYil
Subscribe to:
Post Comments (Atom)
-
Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response with just one ...
-
Three treaties between the US and Hong Kong were suspended, the latest move to pressure China. from Yahoo News - Latest News & Headl...
-
from Yahoo News - Latest News & Headlines https://ift.tt/OlI9Rgs
No comments:
Post a Comment